FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567288769> ?p ?o ?g. }

• W1567288769 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAThe anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor involved in the genesis of several human cancers, is a promising therapeutic target in Neuroblastoma (NB). Many studies on sporadic cases with advanced NB have shown ALK mutated or highly expressed independently of its genetic status (mutated, amplified, wild-type) and its pivotal role in NB growth and survival. As ALK is currently considered a master driver of NB oncogenesis, the use of therapies inhibiting ALK represents a suitable treatment option.The ALK inhibitor Crizotinib was recently approved for the treatment of advanced NSCLC patient. However, as often observed with kinase inhibitors, some patients develop acquired resistance in part due to genetic ALK mutations. To overcome this limitation a selective and more potent ALK inhibitor, X-396, was developed that is currently in phase I clinical trial in adult patients with advanced solid tumors, but it has not been tested in preclinical animal models of NB.We have successfully employed a RNAi-mediated therapeutic approach to selectively knockdown ALK expression by using nanoliposomes entrapping siRNA and coupled with anti-GD2 antibodies to target NB cells. Our data demonstrate for the first time a role of ALK in NB-induced angiogenesis and in tumor invasion.Here, we aimed to test whether the combination of the novel ALK kinase inhibitor X-396 with the liposome-based silencing of ALK could represent a powerful synergistic and or additive effect in NB xenografts to promote long-term survival.In vitro, X-396 showed to be more effective than Crizotinib in inhibiting cell proliferation and in inducing cell death in both LAN-5 (R1275Q ALK mut, Crizotinib-sensitive) and SH-SY5Y (F1174L ALK mut, Crizotinib-resistant) cells.Pharmacokinetic profiles of X-396 after multiple PO administration in NB-xenografts revealed a good bioavailability and a moderate half-life. Biodistribution study clearly indicated that the concentration of X-396 8h post-administration was 35 fold higher in the tumor site than in plasma. X-396 reduced the tumor volume in subcutaneous SH-SY5Y NB-model in a dose-dependent manner and it was more effective than Crizotinib when administered at the same concentration. In orthotopic xenografts of SH-SY5Y and LAN-5 cells, X-396 significantly increased life span. In combination studies, all effects were significantly improved in the mice treated with targeted liposomal formulation of ALK-siRNA and X-396 compared to untreated control mice or mice receiving the single agent treatments. In the latter studies, further enhancement of life span was obtained by increasing the X-396 dose. Moreover, the combined treatment was also proven to be effective in the SH-SY5Y-pseudometastatic model in determining long-term survivors. Our findings provide a rational basis to design innovative molecular-based combination of treatments for clinical application in NB.Citation Format: Daniela Di Paolo, Laura Emionite, George Liu, Michele Cilli, Annarita Di Fiore, Chiara Brignole, Chris Liang, Fabio Pastorino, Jay Gibbons, Mirco Ponzoni, Patrizia Perri. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK . [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2622. doi:10.1158/1538-7445.AM2014-2622" @default.
• W1567288769 created "2016-06-24" @default.
• W1567288769 creator A5000242295 @default.
• W1567288769 creator A5012660765 @default.
• W1567288769 creator A5014918411 @default.
• W1567288769 creator A5022109733 @default.
• W1567288769 creator A5027704478 @default.
• W1567288769 creator A5044319437 @default.
• W1567288769 creator A5053922930 @default.
• W1567288769 creator A5062757807 @default.
• W1567288769 creator A5065117112 @default.
• W1567288769 creator A5070686436 @default.
• W1567288769 creator A5088779262 @default.
• W1567288769 date "2014-09-30" @default.
• W1567288769 modified "2023-09-27" @default.
• W1567288769 title "Abstract 2622: New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs againstALK" @default.
• W1567288769 doi "https://doi.org/10.1158/1538-7445.am2014-2622" @default.
• W1567288769 hasPublicationYear "2014" @default.
• W1567288769 type Work @default.
• W1567288769 sameAs 1567288769 @default.
• W1567288769 citedByCount "0" @default.
• W1567288769 crossrefType "proceedings-article" @default.
• W1567288769 hasAuthorship W1567288769A5000242295 @default.
• W1567288769 hasAuthorship W1567288769A5012660765 @default.
• W1567288769 hasAuthorship W1567288769A5014918411 @default.
• W1567288769 hasAuthorship W1567288769A5022109733 @default.
• W1567288769 hasAuthorship W1567288769A5027704478 @default.
• W1567288769 hasAuthorship W1567288769A5044319437 @default.
• W1567288769 hasAuthorship W1567288769A5053922930 @default.
• W1567288769 hasAuthorship W1567288769A5062757807 @default.
• W1567288769 hasAuthorship W1567288769A5065117112 @default.
• W1567288769 hasAuthorship W1567288769A5070686436 @default.
• W1567288769 hasAuthorship W1567288769A5088779262 @default.
• W1567288769 hasConcept C101544691 @default.
• W1567288769 hasConcept C104317684 @default.
• W1567288769 hasConcept C117643217 @default.
• W1567288769 hasConcept C121608353 @default.
• W1567288769 hasConcept C126322002 @default.
• W1567288769 hasConcept C143998085 @default.
• W1567288769 hasConcept C166703698 @default.
• W1567288769 hasConcept C170493617 @default.
• W1567288769 hasConcept C173396325 @default.
• W1567288769 hasConcept C184235292 @default.
• W1567288769 hasConcept C22615655 @default.
• W1567288769 hasConcept C2776232967 @default.
• W1567288769 hasConcept C2776256026 @default.
• W1567288769 hasConcept C2776715637 @default.
• W1567288769 hasConcept C2778347629 @default.
• W1567288769 hasConcept C2778820342 @default.
• W1567288769 hasConcept C2779422266 @default.
• W1567288769 hasConcept C2779750558 @default.
• W1567288769 hasConcept C42362537 @default.
• W1567288769 hasConcept C502942594 @default.
• W1567288769 hasConcept C54009773 @default.
• W1567288769 hasConcept C54355233 @default.
• W1567288769 hasConcept C67705224 @default.
• W1567288769 hasConcept C71924100 @default.
• W1567288769 hasConcept C81885089 @default.
• W1567288769 hasConcept C86803240 @default.
• W1567288769 hasConceptScore W1567288769C101544691 @default.
• W1567288769 hasConceptScore W1567288769C104317684 @default.
• W1567288769 hasConceptScore W1567288769C117643217 @default.
• W1567288769 hasConceptScore W1567288769C121608353 @default.
• W1567288769 hasConceptScore W1567288769C126322002 @default.
• W1567288769 hasConceptScore W1567288769C143998085 @default.
• W1567288769 hasConceptScore W1567288769C166703698 @default.
• W1567288769 hasConceptScore W1567288769C170493617 @default.
• W1567288769 hasConceptScore W1567288769C173396325 @default.
• W1567288769 hasConceptScore W1567288769C184235292 @default.
• W1567288769 hasConceptScore W1567288769C22615655 @default.
• W1567288769 hasConceptScore W1567288769C2776232967 @default.
• W1567288769 hasConceptScore W1567288769C2776256026 @default.
• W1567288769 hasConceptScore W1567288769C2776715637 @default.
• W1567288769 hasConceptScore W1567288769C2778347629 @default.
• W1567288769 hasConceptScore W1567288769C2778820342 @default.
• W1567288769 hasConceptScore W1567288769C2779422266 @default.
• W1567288769 hasConceptScore W1567288769C2779750558 @default.
• W1567288769 hasConceptScore W1567288769C42362537 @default.
• W1567288769 hasConceptScore W1567288769C502942594 @default.
• W1567288769 hasConceptScore W1567288769C54009773 @default.
• W1567288769 hasConceptScore W1567288769C54355233 @default.
• W1567288769 hasConceptScore W1567288769C67705224 @default.
• W1567288769 hasConceptScore W1567288769C71924100 @default.
• W1567288769 hasConceptScore W1567288769C81885089 @default.
• W1567288769 hasConceptScore W1567288769C86803240 @default.
• W1567288769 hasLocation W15672887691 @default.
• W1567288769 hasOpenAccess W1567288769 @default.
• W1567288769 hasPrimaryLocation W15672887691 @default.
• W1567288769 hasRelatedWork W1553171113 @default.
• W1567288769 hasRelatedWork W1989477491 @default.
• W1567288769 hasRelatedWork W2004978223 @default.
• W1567288769 hasRelatedWork W2044247525 @default.
• W1567288769 hasRelatedWork W2068159188 @default.
• W1567288769 hasRelatedWork W2128386291 @default.
• W1567288769 hasRelatedWork W2193255355 @default.
• W1567288769 hasRelatedWork W2318885229 @default.
• W1567288769 hasRelatedWork W2330423601 @default.
• W1567288769 hasRelatedWork W2330501746 @default.
• W1567288769 hasRelatedWork W2337713490 @default.
• W1567288769 hasRelatedWork W2477053965 @default.

• next